CA2949994A1 - Purified compositions of ivig and kh proteins for modulating lymphocytes and treating hepatitis b virus - Google Patents

Purified compositions of ivig and kh proteins for modulating lymphocytes and treating hepatitis b virus Download PDF

Info

Publication number
CA2949994A1
CA2949994A1 CA2949994A CA2949994A CA2949994A1 CA 2949994 A1 CA2949994 A1 CA 2949994A1 CA 2949994 A CA2949994 A CA 2949994A CA 2949994 A CA2949994 A CA 2949994A CA 2949994 A1 CA2949994 A1 CA 2949994A1
Authority
CA
Canada
Prior art keywords
amino acid
acid sequence
protein
sequence seq
substantially pure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA2949994A
Other languages
English (en)
French (fr)
Inventor
Kieu Hoang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rare Antibody Antigen Supply Inc
Original Assignee
Rare Antibody Antigen Supply Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54699755&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2949994(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Rare Antibody Antigen Supply Inc filed Critical Rare Antibody Antigen Supply Inc
Publication of CA2949994A1 publication Critical patent/CA2949994A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA2949994A 2014-05-28 2015-05-28 Purified compositions of ivig and kh proteins for modulating lymphocytes and treating hepatitis b virus Pending CA2949994A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462003664P 2014-05-28 2014-05-28
US62/003,664 2014-05-28
PCT/US2015/032807 WO2015184050A1 (en) 2014-05-28 2015-05-28 Purified compositions of ivig and kh proteins for modulating lymphocytes and treating hepatitis b virus

Publications (1)

Publication Number Publication Date
CA2949994A1 true CA2949994A1 (en) 2015-12-03

Family

ID=54699755

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2949994A Pending CA2949994A1 (en) 2014-05-28 2015-05-28 Purified compositions of ivig and kh proteins for modulating lymphocytes and treating hepatitis b virus

Country Status (10)

Country Link
EP (1) EP3148574B1 (https=)
JP (1) JP2017525752A (https=)
CN (1) CN107106664A (https=)
AU (1) AU2015266997A1 (https=)
BR (1) BR112016027818A2 (https=)
CA (1) CA2949994A1 (https=)
ES (1) ES2878043T3 (https=)
MX (1) MX2016015574A (https=)
RU (1) RU2016151761A (https=)
WO (1) WO2015184050A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015184050A1 (en) 2014-05-28 2015-12-03 Rare Antibody Antigen Supply, Inc. Purified compositions of ivig and kh proteins for modulating lymphocytes and treating hepatitis b virus
US20160289300A1 (en) * 2015-04-02 2016-10-06 Kieu Hoang Method of manufacturing intravenous immunoglobulin from fraction iii
CN107921080A (zh) * 2015-04-02 2018-04-17 K·黄 由组分iii制造并纯化出用于静脉注射的凝血酶原复合物浓缩剂的方法以及治疗和预防具有抑制剂的a型血友病或感染了hiv‑1和hiv‑2的b型血友病患者的方法
CN118903378A (zh) * 2024-03-19 2024-11-08 北京达尔文细胞生物科技有限公司 一种蛋白聚合物在治疗渐冻症中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3825429C2 (de) * 1988-07-27 1994-02-10 Biotest Pharma Gmbh Verfahren zur Herstellung eines intravenös verabreichbaren polyklonalen Immunglobulin-Präparates mit hohem IgM-Gehalt
US20040142325A1 (en) * 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
GB0315248D0 (en) * 2003-06-30 2003-08-06 Hoffmann La Roche HCV regulated protein expression
TWI489994B (zh) 2008-03-17 2015-07-01 Baxter Healthcare Sa 供免疫球蛋白及玻尿酸酶之皮下投藥之用的組合及方法
CA2639003A1 (en) 2008-08-20 2010-02-20 Canadian Blood Services Inhibition of fc.gamma.r-mediated phagocytosis with reduced immunoglobulin preparations
US10233228B2 (en) * 2010-04-09 2019-03-19 Albumedix Ltd Albumin derivatives and variants
WO2011143637A1 (en) * 2010-05-14 2011-11-17 The Regents Of The University Of Colorado, A Body Corporate Improved complement receptor 2 (cr2) targeting groups
WO2015184050A1 (en) 2014-05-28 2015-12-03 Rare Antibody Antigen Supply, Inc. Purified compositions of ivig and kh proteins for modulating lymphocytes and treating hepatitis b virus
TW201335181A (zh) 2012-01-31 2013-09-01 Kieu Hoang ５５種新發現的蛋白質之序列及其應用

Also Published As

Publication number Publication date
ES2878043T3 (es) 2021-11-18
EP3148574A4 (en) 2017-04-05
MX2016015574A (es) 2018-05-28
RU2016151761A (ru) 2018-07-03
CN107106664A (zh) 2017-08-29
WO2015184050A1 (en) 2015-12-03
EP3148574B1 (en) 2021-04-14
JP2017525752A (ja) 2017-09-07
AU2015266997A1 (en) 2016-12-08
BR112016027818A2 (pt) 2017-10-24
RU2016151761A3 (https=) 2018-12-26
EP3148574A1 (en) 2017-04-05

Similar Documents

Publication Publication Date Title
EP3134120B1 (en) Compositions and methods for treating cytokine-related disorders
JP2019517488A (ja) 医学に使用するためのヒト血小板溶解物由来細胞外小胞
US20190328792A1 (en) Mesenchymal stem cell-derived extracellular vesicles and their medical use
CN105101978A (zh) Nk细胞强化型血液制剂的制造方法
JP5847518B2 (ja) Ｎｋ細胞強化型血液製剤の製造方法
WO2012099093A1 (ja) Nk細胞強化型血液製剤の製造方法
EP3148574B1 (en) Purified compositions of ivig and kh proteins for modulating lymphocytes and treating hepatitis b virus
CN106754723B (zh) 一种具有抗肿瘤功能的免疫细胞及其应用
CN111286488B (zh) 一种自然杀伤细胞体外培养方法
JP2022541293A (ja) がん細胞療法用のｐ２１発現単球
JP4275680B2 (ja) リンパ球の活性・増殖に係る培養方法
CN115120713A (zh) 氢氧化铝-CpG寡核苷酸-多肽复合佐剂、疫苗及制备方法和用途
JP2017520582A (ja) 関節リウマチ治療のための間葉系間質細胞
NZ537382A (en) Extracorporeal photopheresis in combination with anti-TNF treatment
JP5386083B2 (ja) 自己免疫疾患および変性疾患を治療する方法
CN117986351B (zh) 一种ra自身抗原表位多肽及其制备的抗原特异性t细胞疫苗、制备方法和应用
US20180021376A1 (en) Naming of KH1 through KH55 good healthy cells synthesizes the KH1 through KH55 proteins
JP7762964B2 (ja) カクテル樹状細胞ワクチンの製造方法
US20240200030A1 (en) Tumor proximal cell collection
Balestrieri Identification of Galectin-1 as a Marker for Claudin-Low Breast Cancer and Implications for Tumor Progression
Crum Matrix-bound Nanovesicles as an Immunomodulatory Therapy for Rheumatoid Arthritis
Gkanatsiou Identification of immunosuppressive mechanisms in Glioblastoma Mulltiforme brain tumours
CN117448412A (zh) CD158d分子、其中和抗体，及应用
EP1523991B1 (en) Anti-cancer vaccine
CN115305238A (zh) 一种提高自然杀伤细胞杀伤力的成分在自然杀伤细胞培养中的应用

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200519